AgingResearch.NewsJoin free

Foresee Pharmaceuticals

CompanyTaiwan

Foresee Pharmaceuticals develops one asset, approved (CAMCEVI in advanced prostate cancer). Mostly peptide acting on GNRHR; based in Taiwan.

1
Asset
Furthest stage
Approved
0
Trials
1
Signal

Pipeline

1

  • CAMCEVI

    Sustained GnRH receptor agonism suppresses gonadotropin release and testosterone production.

    Approved, Peptide, GNRHR, advanced prostate cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals1
  • Similar companies1

Intelligence